SCHEMBL7022545

SCHEMBL7022545

O=c1c2[nH]cnc2n(C2CCCCC2)c(=O)n1C1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 10/20 0.57
ADORA3 P0DMS8 2/20 0.57
ATAD2 Q6PL18 1/20 0.44
ADORA2A P29274 10/20 0.43
PDE4A P27815 7/20 0.43
PDE4B Q07343 7/20 0.43
PDE4C Q08493 7/20 0.43
PDE4D Q08499 7/20 0.43
PIK3CD O00329 1/20 0.43
ALPL P05186 1/20 0.43
TMIGD3 P0DMS9 1/20 0.43
ADORA1 P30542 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPK1 P28482 2/20 0.40
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
MEN1 O00255 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9351699 0.95 ADORA2B (0.55) ADORA2BADORA3ATAD2ADORA2APDE4A
SCHEMBL18127709 0.92 ADORA2B (0.50) ADORA2BADORA3ATAD2ADORA2APDE4A
SCHEMBL10441214 0.85 ADORA2B (0.51) ADORA2BADORA3ATAD2ADORA2APDE4A
SCHEMBL5005966 0.84 ADORA2A (0.62) ADORA2BADORA3ADORA2APDE4APDE4B
SCHEMBL9354344 0.81 ADORA2B (0.47) ADORA2BADORA3ADORA2APDE4APDE4B
SCHEMBL28755643 0.79 ATAD2 (0.49) ADORA2BADORA3ATAD2ADORA2APDE4A
SCHEMBL9807157 0.79 ATAD2 (0.64) ADORA2BADORA3ATAD2ADORA2APDE4A
SCHEMBL5935784 0.76 ADORA3 (0.61) ADORA2BADORA3ADORA2APDE4APDE4B
SCHEMBL9842805 0.75 ADORA2A (0.67) ADORA2BADORA2APDE4APDE4BPDE4C
SCHEMBL24700880 0.74 ATAD2 (0.57) ADORA2BADORA3ATAD2ADORA2APDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0369744-B1 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GMBH (DE) 1994-09-21 EP claimed
EP-0369744-A2 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GmbH (DE) 1990-05-23 EP claimed
US-6531600-B1 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed BEECHAM GROUP P.L.C. (GB) 2003-03-11 US disclosed
EP-1120417-A2 Xanthine derivatives for the treatment of cerebrovascular disorders SMITHKLINE BEECHAM PHARMA GmbH (DE) 2001-08-01 EP disclosed
US-6180791-B1 REDUCING NITRO GROUPS TO FORM AMINO GROUPS BEECHAM GROUP P.L.C. (GB) 2001-01-30 US disclosed
US-5981535-A FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-09 US disclosed
US-5734051-A TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY BEECHAM GROUP (GB) 1998-03-31 US disclosed
EP-0369744-B1 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GMBH (DE) 1994-09-21 EP disclosed
US-5321029-A Vascular and skin disorders; bronchodilator BEECHAM-WUELFING GMBH & CO.K.G. (DE) 1994-06-14 US disclosed
EP-0389282-A2 Xanthinederivatives, process for their preparation and their pharmaceutical use BEECHAM - WUELFING GmbH & Co. KG (DE) 1990-09-26 EP disclosed
EP-0369744-A2 Xanthine derivatives, process for their preparation and pharmaceutical compositions SMITHKLINE BEECHAM PHARMA GmbH (DE) 1990-05-23 EP disclosed